Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: Peter Singleton who wrote (4267)	5/7/1998 4:09:00 PM
From: Bhag Karamchandani	Respond to of 6136

Peter: Thanks. In the computer industry, as we know, second generation implies improvement or upgrade of an existing in-house product. Marimastat is BBIOY's product.It is difficult to imagine that AGPH knew about the potential limitations (adverse side effects)of Marimastat at the time AGPH started its screening for AG 3340. My guess is that AG3340 represents the best profile/choice amongst AGPH's own competing candidates at a given point in time. If so,they may have newer molecules under investigation which may be an improvement on AG3340. Of course, all of this is pure speculation. I like AGPH strategy to develop cancer drugs which work synergistically with other therapies just like the Aids Cocktail. It would seem that multi variable induced diseases such as different types of cancers may not respond to a single magic bullet. Inhibiting migration of cancer cells may be as important as curtailing blood flow to a tumor and targeting the destruction of majority of cancerous cells. AG3340 appears to do two of these three things well???? Please feel free to correct what I have said if it is misleading.